Irbesartan Hydrochlorothiazide Zentiva (Hydrochlorothiazide, Irbesartan)

Irbesartan, the active ingredient in Irbesartan Hydrochlorothiazide Zentiva, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It treats hypertension, often in combination with hydrochlorothiazide, and is prescribed for adults who need blood‑pressure control.

GNH USA supplies Irbesartan Hydrochlorothiazide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including specialty and community settings.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. - Hypertension requiring combination therapy: provides additive blood‑pressure reduction when monotherapy is insufficient. - Salt‑sensitive hypertension: improves control by combining an ARB with a thiazide diuretic.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Mild gastrointestinal upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Significant electrolyte disturbances: severe hypo‑ or hyper‑kalemia. - Acute renal impairment: sudden decline in kidney function. - Angioedema: swelling of face, lips, tongue, or throat. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: rare cases of agranulocytosis or pancytopenia.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with existing kidney disease. - Electrolyte surveillance: check potassium and sodium levels regularly. - Hepatic impairment: use with caution in severe liver disease. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: concurrent use can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - ACE inhibitors: combined therapy can increase risk of hypotension and renal impairment. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan plasma concentrations.